Pomalidomide

被引：82

作者：

Lacy, Martha Q. ^{[1
]}

McCurdy, Arleigh R. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

来源：

BLOOD | 2013年 / 122卷 / 14期

关键词：

REFRACTORY MULTIPLE-MYELOMA; LENALIDOMIDE PLUS DEXAMETHASONE; LOW-DOSE DEXAMETHASONE; CYTOKINE PRODUCTION; ANTITUMOR-ACTIVITY; THALIDOMIDE; CC-4047; BORTEZOMIB; INHIBITOR; CEREBLON;

D O I：

10.1182/blood-2013-05-484782

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration. This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. This review focuses on the clinical trial data that led to approval and provides advice for treating physicians who are now prescribing this drug for patients.

引用

页码：2305 / 2309

页数：5

共 44 条

[1] Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 [J].

Anderson, G ;

Gries, M ;

Kurihara, N ;

Honjo, T ;

Anderson, J ;

Donnenberg, V ;

Donnenberg, A ;

Ghobrial, I ;

Mapara, MY ;

Stirling, D ;

Roodman, D ;

Lentzsch, S .

BLOOD, 2006, 107 (08) :3098-3105

[2]

[Anonymous], 2012, BLOOD

[3] A phase-2 trial of low-dose pomalidomide in myelofibrosis [J].

Begna, K. H. ;

Mesa, R. A. ;

Pardanani, A. ;

Hogan, W. J. ;

Litzow, M. R. ;

McClure, R. F. ;

Tefferi, A. .

LEUKEMIA, 2011, 25 (02) :301-304

[4]

Berenson JR, 2012, ASH ANN M, V120, P2979

[5]

Corral LG, 1999, J IMMUNOL, V163, P380

[6] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[7] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[8]

Dimopoulos MA, 2012, ASH ANN M, V120

[9] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].

Dimopoulos, Meletios ;

Spencer, Andrew ;

Attal, Michael ;

Prince, H. Miles ;

Harousseau, Jean-Luc ;

Dmoszynska, Anna ;

San Miguel, Jesus ;

Hellmann, Andrzej ;

Facon, Thierry ;

Foa, Robin ;

Corso, Alessandro ;

Masliak, Zvenyslava ;

Olesnyckyj, Marta ;

Yu, Zhinuan ;

Patin, John ;

Zeldis, Jerome B. ;

Knight, Robert D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132

[10] Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism [J].

Escoubet-Lozach, Laure ;

Lin, I-Lin ;

Jensen-Pergakes, Kristen ;

Brady, Helen A. ;

Gandhi, Anita K. ;

Schafer, Peter H. ;

Muller, George W. ;

Worland, Peter J. ;

Chan, Kyle W. H. ;

Verhelle, Dominique .

CANCER RESEARCH, 2009, 69 (18) :7347-7356

← 1 2 3 4 5 →